MY164836A - Genetically modified major histocompatibility complex mice - Google Patents

Genetically modified major histocompatibility complex mice

Info

Publication number
MY164836A
MY164836A MYPI2014000784A MYPI2014000784A MY164836A MY 164836 A MY164836 A MY 164836A MY PI2014000784 A MYPI2014000784 A MY PI2014000784A MY PI2014000784 A MYPI2014000784 A MY PI2014000784A MY 164836 A MY164836 A MY 164836A
Authority
MY
Malaysia
Prior art keywords
genetically modified
human
major histocompatibility
histocompatibility complex
modified major
Prior art date
Application number
MYPI2014000784A
Other languages
English (en)
Inventor
Lynn Macdonald
Andrew J Murphy
Cagan Gurer
John Mcwhirter
Vera Voronina
Faith Harris
Sean Stevens
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY164836A publication Critical patent/MY164836A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2014000784A 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice MY164836A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552587P 2011-10-28 2011-10-28
US201161552582P 2011-10-28 2011-10-28
US201261700908P 2012-09-14 2012-09-14

Publications (1)

Publication Number Publication Date
MY164836A true MY164836A (en) 2018-01-30

Family

ID=47178940

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2014000784A MY164836A (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice
MYPI2017703836A MY178723A (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2017703836A MY178723A (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice

Country Status (27)

Country Link
US (3) US9615550B2 (enExample)
EP (4) EP3563680B1 (enExample)
JP (4) JP6154391B2 (enExample)
KR (3) KR102295746B1 (enExample)
CN (3) CN113564188B (enExample)
AU (3) AU2012324016C1 (enExample)
BR (1) BR112014009259A2 (enExample)
CA (2) CA3074400C (enExample)
CY (2) CY1119657T1 (enExample)
DK (2) DK3262932T3 (enExample)
ES (3) ES2741649T3 (enExample)
HK (1) HK1249712B (enExample)
HR (2) HRP20171761T1 (enExample)
HU (2) HUE045879T2 (enExample)
IL (3) IL232097A (enExample)
LT (2) LT2770821T (enExample)
MX (3) MX391222B (enExample)
MY (2) MY164836A (enExample)
NZ (1) NZ734532A (enExample)
PL (2) PL3262932T3 (enExample)
PT (2) PT2770821T (enExample)
RS (2) RS56656B1 (enExample)
SG (2) SG10201603188SA (enExample)
SI (2) SI3262932T1 (enExample)
SM (2) SMT201700576T1 (enExample)
WO (1) WO2013063346A1 (enExample)
ZA (1) ZA201403085B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CA2853731C (en) 2011-10-28 2021-05-18 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 t-세포 보조-수용체를 발현하는 마우스
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
JP6456351B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ主要組織適合複合体(mhc)クラスi分子を発現する遺伝子導入マウス
KR102370419B1 (ko) 2013-09-23 2022-03-04 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
ES2715949T3 (es) 2013-10-15 2019-06-07 Regeneron Pharma Animales con IL-15 humanizada
JP6236461B2 (ja) * 2013-10-18 2017-11-22 大鵬薬品工業株式会社 Hlaクラスi発現非ヒト動物
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
AU2015256299C1 (en) 2014-05-05 2022-01-06 Regeneron Pharmaceuticals, Inc. Humanized C5 and C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
PL3689140T3 (pl) 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
IL286403B2 (en) 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
HUE067123T2 (hu) 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
US10123518B2 (en) * 2015-04-13 2018-11-13 Regeneron Pharmaceuticals, Inc Genetically modified non-human animals and methods of use thereof
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたlymphocyte-activation gene 3遺伝子を有する非ヒト動物
AU2017228293B2 (en) 2016-02-29 2023-05-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized Tmprss gene
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
CN109456942A (zh) * 2017-09-06 2019-03-12 亘喜生物科技(上海)有限公司 通用型嵌合抗原受体t细胞制备技术
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
KR20240128129A (ko) 2017-09-29 2024-08-23 리제너론 파마슈티칼스 인코포레이티드 인간화 C1q 복합체를 발현하는 비인간 동물
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
FI3823443T3 (fi) 2018-07-16 2024-07-25 Regeneron Pharma Ditra-taudin jyrsijämallit ja niiden käyttö
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
WO2020198397A1 (en) * 2019-03-25 2020-10-01 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
EP4087392A4 (en) * 2020-01-10 2024-02-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Fcアルファ受容体を発現するマウス
WO2022133155A1 (en) * 2020-12-16 2022-06-23 Xenotherapeutics, Inc. Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Tcrβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
KR20250077529A (ko) 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DE69840600D1 (de) 1997-09-16 2009-04-09 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t-zellen
AU752590B2 (en) * 1998-02-17 2002-09-26 Ortho-Mcneil Pharmaceutical, Inc. H2-O modified transgenic animals
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2001027291A1 (en) * 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
ES2389251T3 (es) 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005085438A1 (ja) 2004-03-09 2005-09-15 Nagoya Industrial Science Research Institute ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
JP4830139B2 (ja) * 2006-03-10 2011-12-07 学校法人明治大学 クローン胚の作製方法
NZ547859A (en) * 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
MX2009011500A (es) * 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
ES2665068T3 (es) 2008-03-07 2018-04-24 Regeneron Pharmaceuticals, Inc. Ratones derivados de células ES a partir de inyección de un embrión hospedador diploide
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2153845A1 (en) * 2008-08-13 2010-02-17 Julius-Maximilians-Universität Würzburg Endoglin peptides, vaccines and methods for preparing the same
NO2792236T3 (enExample) * 2009-07-08 2018-04-14
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 t-세포 보조-수용체를 발현하는 마우스
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
KR20160011645A (ko) * 2013-06-03 2016-02-01 떼라벡띠스 MHC 클래스 I, MHC 클래스 II 또는 β2 마이크로글로불린 업스트림 프로모터 서열을 포함하는 렌티바이러스 벡터들
JP6236461B2 (ja) * 2013-10-18 2017-11-22 大鵬薬品工業株式会社 Hlaクラスi発現非ヒト動物
CN107666828B (zh) 2015-04-06 2021-04-09 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答

Also Published As

Publication number Publication date
PL3262932T3 (pl) 2019-10-31
RS56656B1 (sr) 2018-03-30
JP6866409B2 (ja) 2021-04-28
WO2013063346A1 (en) 2013-05-02
ZA201403085B (en) 2025-07-30
CN107254480B (zh) 2021-08-10
JP2019068857A (ja) 2019-05-09
LT3262932T (lt) 2019-08-26
ES2651517T3 (es) 2018-01-26
SI3262932T1 (sl) 2019-09-30
JP2020146041A (ja) 2020-09-17
KR102074145B1 (ko) 2020-02-07
DK2770821T3 (da) 2017-11-27
PT3262932T (pt) 2019-08-26
HK1249712B (en) 2020-06-26
AU2012324016A1 (en) 2013-05-16
CN113564188B (zh) 2025-03-04
AU2012324016C1 (en) 2018-02-15
JP6574457B2 (ja) 2019-09-11
EP3262932B1 (en) 2019-05-15
EP4311833A2 (en) 2024-01-31
US9615550B2 (en) 2017-04-11
NZ719373A (en) 2018-06-29
EP3563680A1 (en) 2019-11-06
EP3563680B1 (en) 2023-08-30
SMT201900478T1 (it) 2019-09-09
IL252022A0 (en) 2017-06-29
CN104039132A (zh) 2014-09-10
HRP20191420T1 (hr) 2019-11-15
EP4311833A3 (en) 2024-05-01
ES2741649T3 (es) 2020-02-11
CA3074400C (en) 2025-03-25
MX376167B (es) 2025-03-07
EP3563680C0 (en) 2023-08-30
AU2016202688A1 (en) 2016-05-19
US10869466B2 (en) 2020-12-22
MX2014004895A (es) 2014-09-12
KR101921126B1 (ko) 2018-11-23
AU2017279797A1 (en) 2018-01-25
SG11201400933VA (en) 2014-04-28
US20200375160A1 (en) 2020-12-03
HRP20171761T1 (hr) 2017-12-29
PT2770821T (pt) 2017-12-18
AU2016202688B2 (en) 2017-09-28
AU2017279797C1 (en) 2021-07-15
IL261239A (en) 2018-10-31
LT2770821T (lt) 2017-12-11
HUE045879T2 (hu) 2020-01-28
ES2962287T3 (es) 2024-03-18
HUE035652T2 (en) 2018-05-28
SI2770821T1 (en) 2018-01-31
EP2770821A1 (en) 2014-09-03
CN113564188A (zh) 2021-10-29
CN104039132B (zh) 2017-06-16
JP2017143840A (ja) 2017-08-24
NZ734532A (en) 2022-12-23
AU2012324016A8 (en) 2016-03-03
EP2770821B1 (en) 2017-09-13
IL261239B (en) 2019-11-28
IL232097A0 (en) 2014-05-28
CY1119657T1 (el) 2018-04-04
CA3074400A1 (en) 2013-05-02
CA2850387A1 (en) 2013-05-02
KR102295746B1 (ko) 2021-09-01
US20170164590A1 (en) 2017-06-15
MX391222B (es) 2025-03-21
IL232097A (en) 2017-06-29
JP2014532412A (ja) 2014-12-08
JP6154391B2 (ja) 2017-06-28
MX355725B (es) 2018-04-27
NZ623456A (en) 2016-05-27
AU2017279797B2 (en) 2020-10-22
KR20200013810A (ko) 2020-02-07
SG10201603188SA (en) 2016-05-30
EP3262932A1 (en) 2018-01-03
MX2020010763A (es) 2022-04-01
BR112014009259A2 (pt) 2020-10-27
US20130111617A1 (en) 2013-05-02
PL2770821T3 (pl) 2018-02-28
AU2012324016B2 (en) 2016-01-28
HK1200272A1 (en) 2015-08-07
RS59082B1 (sr) 2019-09-30
KR20180128494A (ko) 2018-12-03
CY1121869T1 (el) 2020-10-14
DK3262932T3 (da) 2019-08-05
CN104039132B9 (zh) 2017-09-05
KR20140089560A (ko) 2014-07-15
SMT201700576T1 (it) 2018-01-11
CN107254480A (zh) 2017-10-17
MY178723A (en) 2020-10-20

Similar Documents

Publication Publication Date Title
MY164836A (en) Genetically modified major histocompatibility complex mice
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
CY1121223T1 (el) Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
EP4374690A3 (en) Mice expressing humanized t-cell co-receptors
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
MX2017006802A (es) Animales no humanos que expresan el complejo cd3 humanizado.
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
MX2020007021A (es) Receptor quimerico de antigeno anti-cd19 humanizado.
MX2022001201A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
MX2014015679A (es) Roedores con il-7 humanizada.
MX2019002482A (es) Animales geneticamente modificados y metodo para su obtencion.
MX353134B (es) Ratones con receptor de linfocitos t modificados geneticamente.
EP4269602A3 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
MX361533B (es) Anticuerpos anti-cd22.
WO2014122035A3 (en) Induced dendritic cells and uses thereof
SG10201908800YA (en) Non-human animals having humanized fc-gamma receptors
MX2021000586A (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
TH168664A (th) หนูที่มีเมเจอร์ ฮิสโตคอมแพทาบิลิตี้ คอมเพลกซ์ซึ่งถูกดัดแปลงทางพันธุกรรม
NZ766708A (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules